Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, August 10, 2012 - Flucelvax


Submission Type: BLA    Submission ID: 125408/0    Office: OVRR
Influenza Vaccine (MDCK Cells)
Novartis Vaccines and Diagnostics, Inc.
Telecon Date/Time: 10-Aug-2012 10:00 AM        Initiated by FDA? Yes
Telephone Number: 617-871-8325
Communication Categorie(s):
1. Information Request
Telecon Summary:
Request for non-inferiority study statement for 6m - 4yos
Non-FDA Participants: Matt Gollwitzer
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
Novartis was informed that OVRR management has expressed great concerns about modifying V58P16 for the purposes of demonstrating of non-inferiority in children 6 months to less than 4 years old. As such, DVRPA requests a simple paragraph describing a separate clinical study to demonstrating non-inferiority. This paragraph only needs to identify the ages of the subjects, the sample sizes of the study groups, and the approximate dates for protocol submission, study start, and FSR.
DVRPA understands that this statement will only reflect a preliminary clinical plan that Novartis may choose modify during the review of this BLA.
DVRPA requested a response no later than early Monday morning. Novartis was also informed that if their management would like to discuss this situation with OVRR management, they should contact Dr. Theresa Finn.

Page Last Updated: 12/19/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English